References
- AnglicheauDThervetEEtienneI2004CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantationClin Pharmacol Ther754223315116055
- BalramCSharmaASivathasanC2003Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlatesBr J Clin Pharmacol56788312848778
- ChowbayBCumaraswamySCheungYB2003Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipientsPharmacogenetics13899512563178
- FrommMF2000P-glycoprotein: adfense mecanism limiting oral bioavailability and CNS accumulation of drugsInt J Clin Pharmacol Ther38697410706193
- FujinoYJokoSMasudaK1999Cyclosporine microemulsion preconcentrate treatment of patients with Behçet’s diseaseJpn J Ophthalmol433182610482480
- FukuenSFukudaTMauneH2002Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese populationPharmacogenetics12331412042671
- HoffmeyerSBurkOvon RichterO2000Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivoProc Natl Acad Sci USA973473810716719
- JohnstonADavidOJCooneyGF2000Pharmacokinetic validation of neoral absorption profilingTransplant Proc32SupplS536
- KeownPA1999Therapeutic strategies for optimal use of novel immunosuppressantsTransplant Proc311790210371954
- LevyGThervetELakeJ2002Consensus on Neoral C(2): Expert Review in Transplantation (CONCERT) Group. Patient management by Neoral C(2) monitoring: an international consensus statementTransplantation73SupplS121812023608
- MahalatiKBelitskyPSketrisI1999Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantationTransplantation68556210428267
- MarzoliniCPausEBuclinT2004Polymorphisms in human MDR1(P-glycoprotein): recent advances and clinical relevanceClin Pharmacol Ther75133314749689
- MinDIEllingrodVL2002C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjectsTher Drug Monit24400412021632
- MinDIEllingrodVLMarshS2004CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjectsTher Drug Monit26524815385835
- MizukiNOtaMYabukiK2000Localization of the pathogenic gene of Behçet’s disease by microsatellite analysis of three different populationsInvest Ophthalmol Vis Sci413702811053265
- SaekiTUedaKTanigawaraY1993Human P-glycoprotein transports cyclosporin A and FK506J Biol Chem2686077807681059
- SugawaraIKataokaIMorishitaY1988Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16Cancer Res48192692894894
- TakaneHKobayashiDHirotaT2004Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1) geneJ Pharmacol Exp Ther31111798715280437
- TanabeMIeiriINagataN2001Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 geneJ Pharmacol Exp Ther29711374311356939
- ThiebautFTsuruoTHamadaH1987Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissuesProc Natl Acad Sci USA84773582444983
- YatesCRZhangWSongP2003The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patientsJ Clin Pharmacol435556412817518